Patents by Inventor Amy C. H. Lee
Amy C. H. Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9187748Abstract: The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.Type: GrantFiled: March 28, 2014Date of Patent: November 17, 2015Inventors: Thomas W. Geisbert, Amy C. H. Lee, Marjorie Robbins, Vandana Sood, Adam Judge, Lisa E. Hensley, Ian MacLachlan
-
Publication number: 20150315584Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).Type: ApplicationFiled: April 1, 2015Publication date: November 5, 2015Applicant: PROTIVA BIOTHERAPEUTICS, INC.Inventors: Marcia MacDonald, Amy C.H. Lee, lan MacLachlan
-
Patent number: 9035039Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target SMAD4 gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating anemia of inflammation in humans).Type: GrantFiled: December 21, 2012Date of Patent: May 19, 2015Assignee: Protiva Biotherapeutics, Inc.Inventors: Ammen P. Dhillon, Amy C. H. Lee, Ian MacLachlan
-
Patent number: 9023820Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).Type: GrantFiled: January 26, 2010Date of Patent: May 5, 2015Assignee: Protiva Biotherapeutics, Inc.Inventors: Marcia MacDonald, Amy C. H. Lee, Ian MacLachlan
-
Publication number: 20150111945Abstract: The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.Type: ApplicationFiled: March 28, 2014Publication date: April 23, 2015Inventors: Thomas W. Geisbert, Amy C.H. Lee, Marjorie Robbins, Vandana Sood, Adam Judge, Lisa E. Hensley, Ian MacLachlan
-
Patent number: 8999950Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target aldehyde dehydrogenase (ALDH) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating alcoholism in humans).Type: GrantFiled: October 4, 2012Date of Patent: April 7, 2015Assignee: Protiva Biotherapeutics Inc.Inventors: Ian MacLachlan, Amy C. H. Lee
-
Patent number: 8865675Abstract: The present invention provides compositions and methods for the delivery of interfering RNAs such as siRNAs that silence APOB expression in cells such as liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells such as liver cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: GrantFiled: May 12, 2011Date of Patent: October 21, 2014Assignee: Protiva Biotherapeutics, Inc.Inventors: James Heyes, Mark Wood, Alan Martin, Amy C. H. Lee, Adam Judge, Marjorie Robbins, Ian MacLachlan
-
Publication number: 20140248338Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target aldehyde dehydrogenase (ALDH) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating alcoholism in humans).Type: ApplicationFiled: October 4, 2012Publication date: September 4, 2014Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Amy C.H. Lee
-
Patent number: 8716464Abstract: The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.Type: GrantFiled: July 20, 2010Date of Patent: May 6, 2014Inventors: Thomas W. Geisbert, Amy C. H. Lee, Marjorie Robbins, Vandana Sood, Adam Judge, Lisa E. Hensley, Ian MacLachlan
-
Publication number: 20130123339Abstract: The present invention provides compositions and methods for the delivery of interfering RNAs such as siRNAs that silence APOB expression in cells such as liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells such as liver cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: ApplicationFiled: May 12, 2011Publication date: May 16, 2013Applicant: PROTIVA BIOTHERAPEUTICS INCInventors: James Heyes, Mark Wood, Alan Martin, Amy C.H. Lee, Adam Judge, Marjorie Robbins, Ian MacLachlan
-
Patent number: 8236943Abstract: The present invention provides compositions and methods for the delivery of interfering RNAs that silence APOB expression to liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: GrantFiled: June 30, 2010Date of Patent: August 7, 2012Assignee: Protiva Biotherapeutics, Inc.Inventors: Amy C. H. Lee, Adam Judge, Marjorie Robbins, Ed Yaworski, Ian MacLachlan
-
Publication number: 20120184595Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).Type: ApplicationFiled: January 26, 2010Publication date: July 19, 2012Applicant: Protive Biotherapeutics, Inc.Inventors: Marcia MacDonald, Amy C.H. Lee, Ian MacLachlan
-
Patent number: 8188263Abstract: The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.Type: GrantFiled: January 23, 2009Date of Patent: May 29, 2012Assignee: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Adam Judge, Amy C. H. Lee, Vandana Sood
-
Publication number: 20110201667Abstract: The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.Type: ApplicationFiled: July 20, 2010Publication date: August 18, 2011Applicants: Protiva Biotherapeutics, Inc., Trustees of Boston University, United States Army Medical Research and Materiel CommandInventors: Thomas W. Geisbert, Amy C.H. Lee, Marjorie Robbins, Vandana Sood, Adam Judge, Lisa E. Hensley, Ian MacLachlan
-
Publication number: 20110195127Abstract: The present invention provides compositions and methods for the delivery of interfering RNAs that silence APOB expression to liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: ApplicationFiled: June 30, 2010Publication date: August 11, 2011Applicant: Protiva Biotherapeutics, Inc.Inventors: Amy C.H. Lee, Adam Judge, Marjorie Robbins, Ed Yaworski, Ian MacLachlan
-
Publication number: 20110189300Abstract: The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence ApoB expression and methods of using such nucleic acid-lipid particles to silence ApoB expression.Type: ApplicationFiled: May 20, 2010Publication date: August 4, 2011Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Lloyd B. Jeffs, Adam Judge, Amy C.H. Lee, Lorne R. Palmer, Vandana Sood
-
Publication number: 20090270481Abstract: The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.Type: ApplicationFiled: January 23, 2009Publication date: October 29, 2009Applicant: Protiva Biotherapeutics,Inc.Inventors: Ian MacLachlan, Adam Judge, Amy C.H. Lee, Vandana Sood